Right. The patents of SSRI and “atypical” neuroleptics have already expired or will expire soon, which will reduce some of the financial pressure to prescribe them. However, now there’s something sinister in the pipeline, namely the new depot injection forms of the atypicals that are currently promoted and will be promoted in the coming years for things such as first psychotic episode, etc. When the atypical came to market, injections of older neuroleptics were downplayed as somewhat inhuman and so on. Now there’s a new campaign to make injections again more acceptable in standard care.